other material
confidence high
sentiment positive
materiality 0.90
Viking Therapeutics positive Phase 2b VOYAGE data: up to 75% NASH resolution with VK2809 vs 29% placebo (p=0.0001)
Viking Therapeutics, Inc.
- NASH resolution with no worsening of fibrosis: 63-75% for VK2809 groups vs 29% placebo (p<0.05 for each, combined p<0.0001).
- Fibrosis improvement ≥1 stage with no NASH worsening: 44-57% for VK2809 vs 34% placebo (p<0.05 for 5 mg and 10 mg QOD, combined p=0.03).
- Combined endpoint (NASH resolution + fibrosis improvement) achieved by 40-50% vs 20% placebo (p<0.05 for 5 mg, 10 mg QOD, combined p=0.003).
- Liver fat reduction at 52 weeks: mean relative change -37% to -55%; ≥30% reduction in 64-88% of VK2809 patients (all p<0.0001 vs placebo).
- GI adverse events similar to placebo; discontinuation rates low; LDL-C reductions of 20-25% vs placebo (p<0.01).